Michelle Brtekzwiener, APRN
Family · Norfolk, NENPI 1144299041
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $44,411 of the $58,651 with a category attached, or 75.7%. Novo Nordisk accounts for 78.7% of it on its own, with 36 other manufacturers making up the rest. Among family clinicians in NE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 395 payments — averaging $148.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$46K
- Mannkind Corporation$8K
- Lilly USA, LLC$1K
- Corcept Therapeutics$439
- Recordati_rare_diseases_inc.$278
- Abbott$264
- plus $3K from 31 others
What the payments were for
- Consulting fees$1,9803%
- Speaking & faculty fees$44,41176%
- Travel & lodging$5,0649%
- Food & beverage$7,17512%
- Education$210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 127 | $46,178 |
| Mannkind Corporation | 36 | $7,917 |
| Lilly USA, LLC | 75 | $1,050 |
| Corcept Therapeutics | 16 | $439 |
| Recordati_rare_diseases_inc. | 11 | $278 |
| Abbott | 6 | $264 |
| Boehringer Ingelheim | 15 | $229 |
| Aimmune Therapeutics, Inc. | 5 | $223 |
| Bayer | 11 | $194 |
| Amgen | 3 | $142 |
| Idorsia Pharmaceuticals US Inc | 3 | $135 |
| AbbVie | 7 | $127 |
| Xeris Pharmaceuticals, Inc. | 7 | $124 |
| Biohaven Pharmaceutical Holding Company Ltd. | 8 | $120 |
| Collegium Pharmaceutical, Inc. | 3 | $117 |
| Ascensia Diabetes Care US Inc. | 6 | $112 |
| Zealand Pharma US, Inc. | 6 | $107 |
| GRT US Holding, Inc. | 6 | $100 |
| Insulet Corporation | 2 | $93 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $82 |
| Madrigal Pharmaceuticals | 3 | $72 |
| Sanofi-aventis U.S. LLC | 4 | $72 |
| Biohaven Pharmaceuticals, Inc. | 4 | $69 |
| Merck | 4 | $66 |
| AstraZeneca | 4 | $58 |
| Medtronic | 3 | $57 |
| Averitas Pharma Inc. | 3 | $54 |
| Currax Pharmaceuticals LLC | 2 | $30 |
| Pfizer | 1 | $21 |
| Tandem Diabetes Care, Inc. | 1 | $19 |
| Nestle Healthcare Nutrition Inc. | 1 | $18 |
| BETA Bionics, Inc. | 1 | $17 |
| Nevro Corp. | 1 | $17 |
| Eisai Inc. | 1 | $15 |
| Sanofi | 1 | $14 |
| Exact Sciences | 1 | $13 |
| Mayne Pharma Commercial LLC | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$58,651 in reported general payments places this provider in the 95th percentile of 809 family providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 202 | $244,691 |
| MounjaroTirzepatide | 149 | $186,872 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 52 | $91,869 |
| Humalog Kwikpen U-200Insulin Lispro | 60 | $75,238 |
| TrulicityDulaglutide | 55 | $75,129 |
| JardianceEmpagliflozin | 69 | $70,756 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 59 | $62,959 |
| Tresiba Flextouch U-200Insulin Degludec | 44 | $56,127 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 39 | $52,659 |
| FarxigaDapagliflozin Propanediol | 76 | $52,283 |
| KerendiaFinerenone | 37 | $32,725 |
| EliquisApixaban | 29 | $24,200 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $18,487 |
| Novolog FlexpenInsulin Aspart | 53 | $14,921 |
| FiaspInsulin Aspart (Niacinamide) | 14 | $11,129 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Xultophy 100-3.6, Fiasp | $46,178 | $347,688268 claims |
| Lilly USA, LLCMounjaro, Trulicity | $1,050 | $262,001204 claims |
| Boehringer IngelheimJardiance, Jentadueto | $229 | $77,49381 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $72 | $62,95959 claims |
| AstraZenecaFarxiga | $58 | $52,28376 claims |
| BayerKerendia | $194 | $32,72537 claims |
| PfizerEliquis | $21 | $24,20029 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 809 family providers in Nebraska.
Other family in Norfolk
- Chantel CollierFriend$257K
- Stephanie SimonOmaha$157K
- Rebecca NewberryOmaha$156K
- Angela CraigOmaha$35K
- Laura FalconeOmaha$26K
- Ladeana SmedlundBoys Town$21K
- Brittany MatneyOmaha$14K
- Patricia TeeterWahoo$13K
- Mary MetzLincoln$13K
- Sara LegleiterOmaha$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.